Login to Your Account

Financings Roundup

ArGen-X Brings in $37M for Camelid Antibodies

By Cormac Sheridan
BioWorld Today Correspondent

Friday, December 2, 2011
ArGen-X BV raised €27.5 million (US$37.1 million) in a Series B round to move its first two programs into clinical development.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription